Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$113.54

3.31 (3.00%)

13:13
01/10/19
01/10
13:13
01/10/19
13:13

Capital International Investors reports 10% passive stake in Bluebird Bio

In a regulatory filing, Capital International Investors disclosed a 10% stake in Bluebird Bio, which represents 5.48M shares. The filing does not allow for activism.

BLUE Bluebird Bio
$113.54

3.31 (3.00%)

12/03/18
ADAM
12/03/18
NO CHANGE
ADAM
Canaccord has positive expectations for Bluebird after bb 21217 data released
Canaccord analyst John Newman maintained a Buy rating and $250 price target on Bluebird Bio, after the company recently released bb 21217 data. Newman has continued positive expectations for the active programs, and for bb2121's clinical progression. He added that "given the previous bb2121 dose response data, we continue to expect strong response data from the ongoing Phase 2 KarMMa trial, the ongoing Phase 1 CRB-401 trial in RRMM, and future Phase 3 trial." The analyst also noted that Bluebird reported cash and marketable securities of ~$2B, which he believes should be able to fund the company to profitability.
12/06/18
PIPR
12/06/18
DOWNGRADE
Target $120
PIPR
Neutral
Bluebird Bio downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren downgraded Bluebird Bio to Neutral and cut his price target for the shares to $120 from $240. The stock closed Tuesday down $2.85 to $113.65. The company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks," Van Buren tells investors in a research note. And while these are risks worth taking for octorefractory multiple myeloma patients with just days to live, the proposition for beta thalassemia and sickle cell patients "is much more difficult," says the analyst. Further, Van Buren believes that as LentiGlobin launches next year, the "exuberance and hope" of clinical development will soon transition to "high expectations for commercial performance." Key opinion leaders agree that broad uptake of LentiGlobin will be challenging, admits the analyst. He lowered his estimates for LentiGlobin and downgraded Bluebird Bio to Neutral.
12/06/18
12/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
RAJA
12/19/18
INITIATION
Target $165
RAJA
Strong Buy
Bluebird Bio initiated with a Strong Buy at Raymond James
Raymond James initiated Bluebird Bio with a Strong Buy and $165 price target.

TODAY'S FREE FLY STORIES

FDC

First Data

$22.94

0.99 (4.51%)

07:57
01/22/19
01/22
07:57
01/22/19
07:57
Downgrade
First Data rating change  »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HEI

Heico

$80.30

1.08 (1.36%)

07:56
01/22/19
01/22
07:56
01/22/19
07:56
Initiation
Heico initiated  »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSP

E.W. Scripps

$18.38

-0.37 (-1.97%)

07:55
01/22/19
01/22
07:55
01/22/19
07:55
Conference/Events
E.W. Scripps management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

STI

SunTrust

$60.73

2.67 (4.60%)

07:55
01/22/19
01/22
07:55
01/22/19
07:55
Recommendations
SunTrust analyst commentary  »

SunTrust price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:54
01/22/19
01/22
07:54
01/22/19
07:54
Periodicals
Amazon launches direct sales of merchandise in Brazil, Reuters reports »

Amazon has launched…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

STAA

STAAR Surgical

$35.10

0.59 (1.71%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Recommendations
STAAR Surgical analyst commentary  »

Canaccord strongly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:53
01/22/19
01/22
07:53
01/22/19
07:53
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$213.94

2.23 (1.05%)

07:52
01/22/19
01/22
07:52
01/22/19
07:52
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

BX

Blackstone

$32.91

0.28 (0.86%)

07:51
01/22/19
01/22
07:51
01/22/19
07:51
Periodicals
Blackstone CEO doesn't think U.S. on verge of recession, CNBC reports »

Blackstone Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 11

    Feb

RDS.A

Royal Dutch Shell

$61.07

0.89 (1.48%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Downgrade
Royal Dutch Shell rating change  »

Royal Dutch Shell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMAC

DiaMedica Therapeutics

$3.50

-0.16 (-4.37%)

07:50
01/22/19
01/22
07:50
01/22/19
07:50
Hot Stocks
DiaMedica Therapeutics announces publication of paper on KLK1, AIS »

DiaMedica Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.97

2.32 (2.02%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Alexion analyst commentary  »

Credit Suisse sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 04

    Feb

  • 18

    Feb

SMTX

SMTC Corp.

$5.60

0.12 (2.19%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Conference/Events
SMTC Corp. management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TIF

Tiffany

$89.85

4.6 (5.40%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HTHT

Huazhu Group

$34.94

1.94 (5.88%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
Huazhu Group initiated  »

Huazhu Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.97

0.18 (1.41%)

07:49
01/22/19
01/22
07:49
01/22/19
07:49
Initiation
GreenTree Hospitality initiated  »

GreenTree Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.10

-0.135 (-2.58%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Conference/Events
TherapeuticsMD management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

ORTX

Orchard Therapeutics

$13.00

0.2 (1.56%)

07:48
01/22/19
01/22
07:48
01/22/19
07:48
Hot Stocks
Orchard Therapeutics announces OTL-300 data published »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$62.51

1.99 (3.29%)

07:47
01/22/19
01/22
07:47
01/22/19
07:47
Hot Stocks
Jacobs Engineering awarded $93M contract for California WaterFix program »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 19

    Feb

STT

State Street

$71.19

0.07 (0.10%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Recommendations
State Street analyst commentary  »

State Street price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.